Overview
Chaperone Therapeutics, Inc. ("Chaperone") is an early-phase pharmaceutical company founded to develop therapies for diseases associated with protein misfolding by restoring the body's natural balance of the protein folding activity. Many neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, prion diseases, ALS (Lou Gehrig's Disease) and Huntington's disease are characterized by protein misfolding in individuals with environmental exposure to proteotoxic stress or genetic vulnerability to disease. Proteins that guide correct protein folding, the protein chaperones, function as the cellular quality control mechanism to correct protein misfolding and to prevent neuronal cell death. Chaperone is uniquely poised to develop novel drugs to ameliorate neurodegenerative disease based on the pharmacological enhancement of the body's natural protein folding machinery.